<DOC>
	<DOCNO>NCT02991131</DOCNO>
	<brief_summary>This open-label , prospective , multi-center , non-interventional , observational , parallel cohort study intend provide real life data treatment duration , effectiveness safety tedizolid linezolid treat ABSSSI hospitalize patient real practice setting .</brief_summary>
	<brief_title>Sivextro Acute Bacterial Skin Skin Structure Infection ( ABSSSI ) Hospitalized Patients . A Global Observational Study</brief_title>
	<detailed_description>The primary objective study assess treatment duration real life 2 cohort consist patient treat 200 mg daily IV/ PO tedizolid treat 600 mg twice daily IV/PO ( Intravenous/ per oral ) linezolid .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Wound Infection</mesh_term>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Erysipelas</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Adult female male inpatient clinical diagnosis compatible ABSSSI ( cellulitis/erysipelas , major skin abscess wound infection ) clinical suspicion infection Gram positive bacteria ( without laboratory confirmation ) . Patients decision initiate treatment tedizolid phosphate linezolid make per physician 's routine treatment practice . Signed informed consent . Patients participate investigational program intervention outside routine clinical practice . Patients enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute bacterial skin infection</keyword>
	<keyword>Acute Bacterial Skin Skin Structure Infection ( ABSSSI )</keyword>
	<keyword>Abscess</keyword>
	<keyword>Cellulitis</keyword>
	<keyword>Erysipelas</keyword>
	<keyword>Wound infection</keyword>
	<keyword>Methicillin resistant Staphylococcus aureus ( MRSA )</keyword>
</DOC>